Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Haemonetics Corporation

HAE

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Last trade $120.58
Day change -$0.76 (-0.63%)
Day range $117.14 – $122.64
Volume 258,123
Market cap $5.53B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.53B
Price / earnings
53.18×
Price / book
6.15×
Price / sales
4×
EV / sales
4.62×
EV / EBITDA
17.75×

Profitability

Earnings per share
$2.28
Return on assets
4.31%
Return on equity
11.56%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.25×
Current ratio
2.84×
Quick ratio
1.83×
Cash ratio
0.87×

Cash flow

Price / cash flow
16.02×
Price / free cash flow
20.06×
Free cash flow
$275.5M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HAE, quarterly periods
Line itemQ2 FY2027 Sep 26, 2026Q1 FY2027 Jun 27, 2026Q4 FY2026 Mar 28, 2026Q3 FY2026 Dec 27, 2025Q2 FY2026 Sep 27, 2025Q1 FY2026 Jun 28, 2025Q4 FY2025 Mar 29, 2025Q3 FY2025 Dec 28, 2024
Revenue$357.76M$339.38M$346.35M$338.97M$327.32M$321.39M$330.6M$348.54M
Cost of revenue$147.25M$136.58M$148.14M$136.58M$143.75M$129.15M$137.55M$155M
Gross profit$210.51M$202.8M$198.21M$202.39M$183.56M$192.24M$193.05M$193.55M
Selling, general and administrative$118.36M$118.94M$120.93M$109.15M$101.62M$110.72M$115.14M$106.46M
Research and development$17.03M$16.2M$14.45M$14.19M$14.87M$16.26M$18.31M$15.83M
Total operating expenses$135.39M$145.35M$221.24M$134.99M$125.07M$138.37M$121.72M$134.52M
Operating income$75.12M$57.46M-$23.03M$67.4M$58.49M$53.87M$71.34M$59.03M
Interest expense-$12.26M-$9.88M$0$0-$7.21M-$8.7M$0$0
Income before taxes$62.86M$47.57M-$28.4M$59.98M$51.29M$45.17M$70.74M$49.92M
Income taxes$16.55M$14.56M-$8.25M$15.24M$12.6M$11.14M$12.76M$12.42M
Net income$46.31M$33.01M-$20.15M$44.74M$38.68M$34.03M$57.98M$37.49M
Net income attributable to common shareholders$46.31M$33.01M-$20.15M$44.74M$38.68M$34.03M$57.98M$37.49M
EBITDA$102.88M$84.57M$75.73M$96.82M$95.33M$82.63M$87.22M$91.4M
Basic earnings per share$1.02$0.73-$0.44$0.96$0.81$0.71$1.18$0.75
Diluted earnings per share$1.00$0.72-$0.43$0.95$0.81$0.70$1.17$0.74

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) reported quarterly earnings of $1.35 per share, beating consensus estimates of $1.30, with revenues of $357.76 million exceeding expectations by 3.15%. The company has outperformed market estimates in four consecutive quarters and gained 59% year-to-date. However, the Medical-Products industry ranks in the bottom 36% of Zacks industries, which could limit future performance despite HAE's Zacks Rank #2 (Buy) rating.

Zacks Investment Research

GEHC vs. HAE: Which Stock Is the Better Value Option?

In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) and Haemonetics (HAE), both holding a Zacks Rank #2 (Buy), GEHC emerges as the superior value option. GEHC has a lower forward P/E ratio of 15.33 compared to HAE's 22.35, a better PEG ratio of 2.00 versus 2.37, and a more favorable P/B ratio of 2.94 versus 6.42, earning it a Value grade of B compared to HAE's C grade.

Zacks Investment Research

All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy

Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The company, which provides blood management systems, is positioned in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential near-term stock price appreciation.

Zacks Investment Research

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?

Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures.

Zacks Investment Research

Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term

Haemonetics Corporation (HAE), a blood management solutions provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a B VGM Score. The stock has gained 14.8% over the past four weeks, driven by positive momentum. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $5.29 per share for fiscal 2027, and the company maintains a +6% average earnings surprise.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 3, 20122-for-1forward split